# A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

> **NCT03292016** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** APL-130277
- **DRUG:** APO-go
- **DRUG:** Apokyn

## Key facts

- **NCT ID:** NCT03292016
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-22
- **Primary completion:** 2019-03-05
- **Final completion:** 2019-03-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292016, "A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03292016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*